Literature DB >> 1907250

von Willebrand factor and development of diabetic nephropathy in IDDM.

C D Stehouwer1, E S Stroes, W H Hackeng, P G Mulder, G J Den Ottolander.   

Abstract

We tested the hypothesis that dysfunction of vascular endothelium, indicated by an increase in plasma level of von Willebrand factor (vWF), is present in patients with insulin-dependent diabetes mellitus (IDDM) who develop diabetic nephropathy (DN). DN was classified as absent (urinary albumin excretion [UAE] rate less than 15 microgram/min), incipient (UAE rate 15-200 micrograms/min), or clinical (UAE rate greater than 200 micrograms/min). We followed a cohort of 59 patients for a median of 3 yr. At baseline, 52 patients had no DN, 6 had incipient DN, and 1 had clinical DN. At follow-up, 38 patients had no DN (group 1). Incipient DN had developed in 14 patients and worsened in 3 patients. Clinical DN had worsened in 1 patient. Together, these 18 patients comprised group 2. A decrease in UAE was observed in the remaining three patients with incipient DN at baseline (group 3). In group 1, vWF--measured by immunoelectrophoresis and expressed as a percentage of normal--increased slightly (median 10%, range -43 to 145, P = 0.009). In group 2, vWF increased in all patients (median 80%, range 14 to 206 [corrected], P = 0.0002 vs. baseline and group 1). In group 3, vWF decreased (median -19%, range -44 to -18). After correction for possible confounders, i.e., age, varying duration of follow-up, and initial level of vWF, the difference in vWF change between groups 1 and 2 remained significant (P = 0.009). Poor glycemic control at baseline, estimated by glycosylated hemoglobin, was a significant predictor of increases in vWF in both group 1 and groups 1 and 2 combined.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907250     DOI: 10.2337/diab.40.8.971

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  16 in total

Review 1.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Endothelial dysfunction as a potential contributor in diabetic nephropathy.

Authors:  Takahiko Nakagawa; Katsuyuki Tanabe; Byron P Croker; Richard J Johnson; Maria B Grant; Tomoki Kosugi; Qiuhong Li
Journal:  Nat Rev Nephrol       Date:  2010-11-02       Impact factor: 28.314

3.  Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

Authors:  P Rossing
Journal:  Diabetologia       Date:  2005-12-09       Impact factor: 10.122

4.  Elevated von Willebrand factor antigen predicts deterioration in diabetic peripheral nerve function.

Authors:  M E Plater; I Ford; M T Dent; F E Preston; J D Ward
Journal:  Diabetologia       Date:  1996-03       Impact factor: 10.122

Review 5.  Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.

Authors:  Sandra J Hamilton; Gerald F Watts
Journal:  Rev Diabet Stud       Date:  2013-08-10

6.  Acute hyperhomocysteinaemia affects pulse pressure but not microvascular vasodilator function.

Authors:  K R Davis; H Pearson; S Moat; J R Bonham; R Donnelly
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

7.  von Willebrand factor and early diabetic retinopathy: no evidence for a relationship in patients with type 1 (insulin-dependent) diabetes mellitus and normal urinary albumin excretion.

Authors:  C D Stehouwer; P Zellenrath; B C Polak; G S Baarsma; J J Nauta; A J Donker; G J den Ottolander
Journal:  Diabetologia       Date:  1992-06       Impact factor: 10.122

8.  Endothelial function in the isolated perfused mesentery and aortae of rats with streptozotocin-induced diabetes: effect of treatment with the aldose reductase inhibitor, ponalrestat.

Authors:  P D Taylor; A D Wickenden; D J Mirrlees; L Poston
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

9.  Effects of fenofibrate on albuminuria in patients with hypertriglyceridemia and/or hyperuricemia: a multicenter, randomized, double-blind, placebo-controlled, crossover study.

Authors:  Tsutomu Kazumi; Tsutomu Hirano; Gen Yoshino
Journal:  Curr Ther Res Clin Exp       Date:  2003-07

10.  Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes.

Authors:  Olaf Brouwers; Petra M G Niessen; Toshio Miyata; Jakob A Østergaard; Allan Flyvbjerg; Carine J Peutz-Kootstra; Jonas Sieber; Peter H Mundel; Michael Brownlee; Ben J A Janssen; Jo G R De Mey; Coen D A Stehouwer; Casper G Schalkwijk
Journal:  Diabetologia       Date:  2013-10-26       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.